Experimental drug shows promise for rare muscle diseases

NCT ID NCT04628936

Completed Disease control Sponsor: Kezar Life Sciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the long-term safety and effectiveness of a drug called KZR-616 in 18 adults with active polymyositis or dermatomyositis, rare diseases that cause muscle inflammation and weakness. Participants who completed an earlier study received weekly injections of KZR-616 for up to 48 weeks. The main goal was to see if the drug improved muscle function and disease activity over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: KZR-616 (zetomipzomib), a drug given as a weekly injection under the skin
What this could lead to: If successful, this could point toward a new treatment option for people with polymyositis or dermatomyositis, helping to control disease activity.
What could go wrong: This is a small, early-phase study with only 18 participants and no placebo comparison, so results may not apply broadly. The drug may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dermatomyositis muscle tissue disorder musculoskeletal system disorder myositis disease polymyositis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DERMATOMYOSITIS POLYMYOSITIS

Contacts and locations

Locations

KZR Research Site

Beverly Hills, California, 90211, United States
KZR Research Site

Orange, California, 92868, United States
KZR Research Site

Miami, Florida, 33136, United States
KZR Research Site

Kansas City, Kansas, 66160, United States
KZR Research Site

Baltimore, Maryland, 21224, United States
KZR Research Site

Ann Arbor, Michigan, 48109, United States
KZR Research Site

Duncansville, Pennsylvania, 16635, United States
KZR Research Site

Pittsburgh, Pennsylvania, 15213, United States
KZR Research Site

Austin, Texas, 78756, United States
KZR Research Site

Prague, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.